The 'big pharma' dilemma: Develop new drugs or promote existing ones?

Nature Reviews Drug Discovery

Volumn 8, Issue 7, 2009, Pages 533-534

  Weiss, Dan ^a   Naik, Prasad ^b   Weiss, Ram ^c  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HEBREW UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

ARTICLE; DRUG DESIGN; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; FINANCIAL MANAGEMENT; INVESTMENT; PERSONNEL MANAGEMENT; PRIORITY JOURNAL; PROFIT; RESOURCE ALLOCATION; RESOURCE MANAGEMENT;

DRUG DISCOVERY; DRUG INDUSTRY; RESEARCH; RESOURCE ALLOCATION;

EID: 67650021216     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2923     Document Type: Article

References (12)

1. Loscalzo, J. The NIH budget and the future of biomedical research. N. Engl. J. Med. 354, 1665-1667 (2006).
2. DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185 (2003).
3. Sewing, A. et al. Helping science to succeed: Improving processes in R&D. Drug Discov. Today 13, 227-233 (2008).
4. Gagnon, M. A. & Lexchin, J. The cost of pushing pills: A new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med. 5, e1 (2008).
5. Donohue, J.M., Cevasco, M. & Rosenthal, M.B. A decade of direct-to-consumer advertising of prescription drugs. N. Engl. J. Med. 357, 673-681 (2007).
6. Wharton Research Data Services (WRDS) [online], (2009).
7. Lev, B. Intangibles: Management, Measurement, and Reporting (Brookings Institution Press, Washington D.C., 2001).
8. Chan, L.K.C., Lakonishok, J. & Sougiannis, T. The stock market valuation of research and development expenditures. J. Finance LVI(6), 2431-2456 (2001).
9. Bebchuk, L. A. & Fried, J. M. Pay Without Performance (Harvard University Press, Massachusetts, 2006).
10. Kothari, S.P., Laguerre, T.E. & Leone, A.J. Capitalization versus expensing: Evidence on the uncertainty of future earnings from capital expenditures versus R&D outlays. Rev. Account Stud. 7, 355-382 (2002).
11. Lev, B. & Sougiannis, T. The capitalization, amortization and value-relevance of R&D. J. Account Econ. 21, 107-138 (1996).
12. Cuatrecasas, P. Drug discovery in jeopardy. J. Clin. Invest. 116, 2837-2842 (2006).